On November 24, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab ...

Fujitsu Limited today announced the development of a multi-AI agent collaboration technology that enables secure collaboration and swift response to changing circumstances among AI agents from ...

Osteoporosis refers to the loss of bone density in the human skeleton. With approximately six million people affected in ...

November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), ...

The Food and Drug Administration (FDA) has approved Osvyrti ® (denosumab-desu), a biosimilar to Prolia ® (denosumab), and Jubereq ® (denosumab-desu), a biosimilar to Xgeva ® (denosumab). Osvyrti is ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alvotech (ALVO) on Monday said that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva (denosumab). Denosumab is widely used to manage osteoporosis and to prevent ...

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

Thiruvananthapuram: Kerala has launched the online mop-up counselling process for PG Pharmacy (M.Pharm) admissions for the ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...